1,811 reports of this reaction
10.5% of all GEFITINIB reports
#1 most reported adverse reaction
MALIGNANT NEOPLASM PROGRESSION is the #1 most commonly reported adverse reaction for GEFITINIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 1,811 FDA adverse event reports linking GEFITINIB to MALIGNANT NEOPLASM PROGRESSION. This represents approximately 10.5% of all 17,300 adverse event reports for this drug.
Patients taking GEFITINIB who experience malignant neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT NEOPLASM PROGRESSION is a frequently reported adverse event for GEFITINIB, accounting for a significant proportion of all reports.
In addition to malignant neoplasm progression, the following adverse reactions have been reported for GEFITINIB:
The following drugs have also been linked to malignant neoplasm progression in FDA adverse event reports:
MALIGNANT NEOPLASM PROGRESSION has been reported as an adverse event in 1,811 FDA reports for GEFITINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT NEOPLASM PROGRESSION accounts for approximately 10.5% of all adverse event reports for GEFITINIB, making it one of the most commonly reported side effect.
If you experience malignant neoplasm progression while taking GEFITINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.